Flow Cytometry System Makes Cell Sorting Easier and More Accessible
|
By Labmedica staff writers Posted on 31 Jan 2008 |

Image: The BD FACSAria II cell-sorting system, designed for consistent results in sorting across a broad range of applications (Photo courtesy of BD Biosciences).
A high-performance flow cytometry system makes cell sorting easier and more accessible to scientists working across a wide range of applications from diagnostics to pure scientific research.
The first generation BD FACSAria system, which was developed in 2003, brought cell sorting to a broader audience of scientists. The next generation high-performance cell sorter, which was launched in January 2008, is the BD FACSAria II flow cytometry system. It features a number of improvements, which were designed across the system to make BD FACSAria II easier to use and more productive.
The BD FACSAria design is based on a true fixed-alignment flow cell that is gel-coupled to the collection optics. This design minimizes startup time, improves experiment-to-experiment reproducibility, and increases the sensitivity and resolution needed for multicolor applications. BD Biosciences (San Jose, CA, USA), the company that designed and manufactures the cell sorters, offers consulting and support services for technical and application needs and compatible, state-of-the-art instruments, as well as a full line of assays and reagents.
The BD FACSAria II incorporates a new fluidics design that improves aseptic setup and cleaning. New nozzle sizes enable a wide range of particles to be sorted and new nozzle design allows for reproducible insertions. Software wizards and automation simplify aseptic sort setup, drop delay determination, and clog detection.
The new model cell sorter improves both workflow and productivity with improvements across the platform. For example, a universal sort tube collection mount now makes it easier to insert and remove tube holders. In addition, software improvements dramatically cut the time spent on cytometer setup, adjustment, and maintenance.
For aerosol management the BD FACSAria II features a sealed pathway from the sample injection chamber to the sort collection tubes. The BD aerosol management option (AMO) evacuates the sort collection chamber and traps aerosolized particles during sorting.
The sample is introduced via the sample injection chamber into the flow cytometer. During acquisition, the chamber is pressurized, forcing the sample to the cuvette flow cell. Sample injection chamber temperature control and agitation are standard with the BD FACSAria II cell sorter. The BD FACSDiva software controls both sample agitation and temperature settings. It also automates quality control and experiment setup.
The 375-nm near ultra violet (UV) laser option is available to expand the range of application choices. The beam geometry is optimized for most hematopoietic stem cells. The top hat design of the 375 nm near UV laser triples the amount of light at the sample intercept. The 375 nm near UV laser can be operated together with the red and blue lasers.
For many users, the capability of an advanced cell sorter is defined by its flexibility, which in turn is defined by the number of parameters that can be detected simultaneously. To provide maximum flexibility, the BD FACSAria II cell sorter can be configured with up to four air-cooled, solid state lasers and can detect up to 15 parameters simultaneously--13 fluorescent markers and two scatter parameters when fully equipped.
The current BD FACSAria cell sorter is field-upgradeable to the BD FACSAria II cell sorter.
Related Links:
BD Biosciences
The first generation BD FACSAria system, which was developed in 2003, brought cell sorting to a broader audience of scientists. The next generation high-performance cell sorter, which was launched in January 2008, is the BD FACSAria II flow cytometry system. It features a number of improvements, which were designed across the system to make BD FACSAria II easier to use and more productive.
The BD FACSAria design is based on a true fixed-alignment flow cell that is gel-coupled to the collection optics. This design minimizes startup time, improves experiment-to-experiment reproducibility, and increases the sensitivity and resolution needed for multicolor applications. BD Biosciences (San Jose, CA, USA), the company that designed and manufactures the cell sorters, offers consulting and support services for technical and application needs and compatible, state-of-the-art instruments, as well as a full line of assays and reagents.
The BD FACSAria II incorporates a new fluidics design that improves aseptic setup and cleaning. New nozzle sizes enable a wide range of particles to be sorted and new nozzle design allows for reproducible insertions. Software wizards and automation simplify aseptic sort setup, drop delay determination, and clog detection.
The new model cell sorter improves both workflow and productivity with improvements across the platform. For example, a universal sort tube collection mount now makes it easier to insert and remove tube holders. In addition, software improvements dramatically cut the time spent on cytometer setup, adjustment, and maintenance.
For aerosol management the BD FACSAria II features a sealed pathway from the sample injection chamber to the sort collection tubes. The BD aerosol management option (AMO) evacuates the sort collection chamber and traps aerosolized particles during sorting.
The sample is introduced via the sample injection chamber into the flow cytometer. During acquisition, the chamber is pressurized, forcing the sample to the cuvette flow cell. Sample injection chamber temperature control and agitation are standard with the BD FACSAria II cell sorter. The BD FACSDiva software controls both sample agitation and temperature settings. It also automates quality control and experiment setup.
The 375-nm near ultra violet (UV) laser option is available to expand the range of application choices. The beam geometry is optimized for most hematopoietic stem cells. The top hat design of the 375 nm near UV laser triples the amount of light at the sample intercept. The 375 nm near UV laser can be operated together with the red and blue lasers.
For many users, the capability of an advanced cell sorter is defined by its flexibility, which in turn is defined by the number of parameters that can be detected simultaneously. To provide maximum flexibility, the BD FACSAria II cell sorter can be configured with up to four air-cooled, solid state lasers and can detect up to 15 parameters simultaneously--13 fluorescent markers and two scatter parameters when fully equipped.
The current BD FACSAria cell sorter is field-upgradeable to the BD FACSAria II cell sorter.
Related Links:
BD Biosciences
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







